We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals

205 hedge funds and large institutions have $3.32B invested in Xenon Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 85 increasing their positions, 52 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more capital inflows, than outflows

Capital inflows: $635M | Capital outflows: $250M

147% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 19

63% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 52

56% more funds holding in top 10

Funds holding in top 10: 9 → 14 (+5)

14% more funds holding

Funds holding: 180 → 205 (+25)

1.91% more ownership

Funds ownership: 95.63% → 97.55% (+1.9%)

4% less call options, than puts

Call options by funds: $39M | Put options by funds: $40.6M

Holders
205
Holders Change
+25
Holders Change %
+13.89%
% of All Funds
2.98%
Holding in Top 10
14
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+55.56%
% of All Funds
0.2%
New
47
Increased
85
Reduced
52
Closed
19
Calls
$39​M
Puts
$40.6​M
Net Calls
-⁠$1.6​M
Net Calls Change
+$6.69​M

XENE Hedge Fund Activity: Q4 2023 in Review

205 of the 6,880 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2023, worth a combined $3.32B — up 58% from $2.1B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new XENE positions and 19 closed out — a net gain of 28 holders — while 85 added to existing stakes and 52 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $86M. The largest seller was BVF Inc, cutting an estimated $33.1M.

  • 205 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2023, up from 180 in Q3 2023.
  • Funds reported $3.32B of Xenon Pharmaceuticals stock for Q4 2023, up 58% quarter-over-quarter.
  • 47 funds opened new Xenon Pharmaceuticals positions in Q4 2023 and 19 closed out, a net change of +28 holders.
  • The largest Xenon Pharmaceuticals buyer in Q4 2023 was Wellington Management Group, an estimated $86M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2023 was BVF Inc, an estimated $33.1M sold.

Based on aggregated 13F filings for Q4 2023.